Drawing for CELLFX

USPTO serial 88415240

CELLFX

Reviewed by CopyMark Law Group

Reg. 5981292Status 702Registered
Filing date
Status date
Registration date
Feb 11, 2020
Examiner
JACKSON, WILLIAM D
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with CELLFX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Lena Vinitskaya

3957 POINT EDEN WAYHAYWARD, CA 94545United States

Goods and services

ClassDescriptionStatusFirst use
010Medical apparatus and devices for treatment in the nature of pulsed electrical destruction or reduction of benign and non-benign biological tissues; medical devices using pulsed electricity for use in treating skin growth, skin lesions and skin conditions; medical devices, namely, medical pulse generators and pulse generator circuits for tissue modification, manipulation and/or ablation; medical apparatus designed for use with nanopulse electricity for manipulation, modification and/or ablation of biologic tissue; medical apparatus, devices and instruments utilizing electrical pulsing technology for [ prevention, detection, diagnosis and] treatment of medical disease, injuries, abnormalities and conditions, namely, tumors, skin and tissue disorders, and other tissue and skin growths; medical systems comprising medical devices and instruments in the nature of pulse generators, pulse generator circuits, medical probes, medical wands, medical electrodes and microneedle treatment tips for use in tissue modification, manipulation and /or ablation; medical pulse generators and medical electrodes for nanosecond pulse delivery for treatment of medical conditions or cosmetic tissue defects; medical device accessories to enable treatment of biological tissues, namely, microneedle treatment tips and medical handpieces; medical and surgical devices and accessories for placement of medical electrodes on tumors, lesions, tissue growth, internal and external anatomical areas comprised of one or more of the following pieces of equipment, namely, medical electrodes, electric medical connectors, medical handpieces, medical probes and guides; all of which exclude apparatus and devices for the treatment of celluliteACTIVEMar 6, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 26, 2025NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Oct 26, 2025C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Oct 26, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 25, 2025E815TEAS SECTION 8 & 15 RECEIVED—
Feb 11, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Feb 11, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 26, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 26, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 6, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 18, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 10, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 10, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 6, 2019ALIEASSIGNED TO LIE—
Sep 28, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 17, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 17, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 17, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 16, 2019DOCKASSIGNED TO EXAMINER—
May 21, 2019MDSMNOTICE OF DESIGN SEARCH CODE E-MAILED—
May 20, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 7, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance